Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.50 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107917 | 0.99 | KDM4E (0.50) | KDM4EALDH1A1ALOX15HSD17B10CYP26A1 | |
| SCHEMBL5114834 | 0.91 | KDM4E (0.48) | KDM4EALDH1A1ALOX15HSD17B10CYP26A1 | |
| SCHEMBL5105219 | 0.87 | HRH3 (0.53) | CYP2D6DRD2DRD1DRD4 | |
| SCHEMBL5115833 | 0.86 | ESR1 (0.56) | KDM4EALDH1A1ALOX15HSD17B10CYP26A1 | |
| SCHEMBL5101348 | 0.86 | HRH3 (0.53) | CYP2D6DRD2DRD1DRD4 | |
| SCHEMBL5108458 | 0.83 | KDM4E (0.72) | KDM4EALDH1A1ALOX15HSD17B10CYP2D6 | |
| SCHEMBL5103000 | 0.80 | BCHE (0.41) | DRD2DRD1DRD4SIGMAR1KMT2A | |
| SCHEMBL5102997 | 0.80 | SLC6A2 (0.40) | KDM4ECYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL5108032 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1ALOX15HSD17B10CYP26A1 | |
| SCHEMBL5102395 | 0.79 | SLC6A2 (0.39) | KDM4ECYP3A4CYP2D6CYP2C19DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1163225-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055137-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | KDM4E 986/4885ALDH1A1 1394/4885ALOX15 3493/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | KDM4E 734/4885ALDH1A1 1511/4885ALOX15 3089/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | KDM4E 663/4885ALDH1A1 1577/4885ALOX15 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.